Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799206 | 0.81 | PARP1 (0.46) | DRD2SIGMAR1DRD4 | |
| SCHEMBL13891500 | 0.74 | HTR1A (0.50) | HTR1ADRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL13799210 | 0.72 | KCNA3 (0.33) | — | |
| SCHEMBL13891539 | 0.70 | DRD2 (0.48) | HTR1ADRD2HTR2ADRD3SIGMAR1 | |
| SCHEMBL13799205 | 0.70 | KMT2A (0.40) | DRD4 | |
| SCHEMBL13799234 | 0.69 | ALDH1A1 (0.32) | — | |
| SCHEMBL10857838 | 0.69 | SIGMAR1 (0.69) | HTR1ADRD2HTR2ASIGMAR1KCNH2 | |
| SCHEMBL14264173 | 0.68 | MAPT (0.41) | — | |
| SCHEMBL10739006 | 0.66 | DRD3 (0.94) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL4528457 | 0.66 | KCNH2 (1.00) | HTR1ADRD2HTR2ADRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | PARP1, PARP2, PARP3 | HTR1A 2229/4885DRD2 4783/4885HTR2A 2805/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | HTR1A 1869/4885DRD2 3532/4885HTR2A 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.